Skip to main content

Inito

Category: AI in Healthcare

An AI-powered fertility monitor that enables smartphone-based, lab-grade hormone testing at home to predict and confirm ovulation using AI-designed antibodies Inito was founded in 2015. The company is led by Aayush Rai. Based in Bengaluru, India. Team size: 100-200. Total funding raised: $45M. Latest round: Series B, $29.0M, 2025-12, led by Bertelsmann India Investments. Key investors include ["Bertelsmann India Investments","Fireside Ventures","Y Combinator"].

Founded
2015
Headquarters
Bengaluru, India
Team size
100-200
Total funding
$45M

Value proposition

The only at-home fertility test that both predicts and confirms ovulation by measuring multiple hormones (estrogen, LH, PdG, FSH) with medical-grade accuracy, eliminating clinic visits while providing personalized AI-driven cycle predictions

Products and solutions

["Inito Fertility Monitor - Multi-hormone tracking device","AI-Powered Analytics App - Personalized cycle predictions","Flat-lens Diagnostic Platform - Expandable to diabetes, thyroid, vitamin D tests","AI-Designed Antibody Test Strips - Enhanced specificity and sensitivity"]

Unique value

Only fertility monitor that confirms ovulation (not just predicts) by measuring progone metabolite (PdG), uses AI-designed antibodies for enhanced detection, and combines multiple hormone tracking in a single test strip

Target customer

Women and couples trying to conceive, fertility clinics, telehealth platforms, and health-conscious women seeking personalized cycle insights

Industries served

["FemTech","Home Diagnostics","Reproductive Health","Digital Health","Medical Devices"]

Technology advantage

Patented flat-lens optical technology enables dozens of diagnostic tests on one smartphone-connected device, while AI algorithms personalize predictions and detect anomalies like anovulation or luteal phase defects

How they differentiate

AI-driven multi-hormone testing platform using single test strip to measure 4 key fertility hormones (LH, E3G, PdG, FSH) with smartphone-based optical reader, evolving from fertility tracking to broader health diagnostics using AI-designed antibodies

Main competitors

["Mira Fertility","Clearblue Fertility Monitor","Proov"]

Key partnerships

["US FDA - Class I medical device registration","Y Combinator - Accelerator program and global network","IIT Delhi - Clinical validation studies","Fireside Ventures - Series A funding and strategic guidance","Bertelsmann India Investments - Series B funding lead"]

Notable customers

["75,000+ couples using Inito fertility monitor","Direct-to-consumer TTC couples","Clinicians seeking hormone data sharing capabilities"]

Major milestones

["Raised $29M Series B in Dec 2025 led by Bertelsmann India Investments","Secured $6M Series A in Nov 2023 led by Fireside Ventures","FDA Class I medical device registration achieved","Developed AI-designed antibody technology for expanded health testing","30+ million hormone data points analyzed since 2021"]

Growth metrics

Analyzing 30+ million fertility hormone data points since 2021, expanding from fertility tracker to broader hormone diagnostics platform using AI-designed antibodies, $22.7M ARR in 2024

Market positioning

Mid-market clinical-grade fertility monitor positioned between premium dedicated-reader solutions (Mira) and mass-market OPKs (Clearblue), targeting data-seeking TTC couples with irregular cycles/PCOS

Geographic focus

Primarily US and English-speaking markets with high iOS penetration, competing most intensely in DTC digital-first fertility segments

Patents and IP

Multiple patents including flat-lens optical system, proprietary immunoassay designs for multi-hormone detection, AI-based cycle modeling algorithms, and modular diagnostic platform architecture

About Aayush Rai

Research Engineer at Siemens (2012-2015), Co-founded Inito in 2015 after graduating from IIT Roorkee with expertise in medical devices and health technology. Forbes 30 Under 30 Asia - Healthcare & Science (2019), Y Combinator Alumni (2019 batch)

Official website: